Pancragen 20 mg

Pancragen is a short peptide bioregulator developed within the Khavinson school of peptide research at the Saint Petersburg Institute of Bioregulation and Gerontology. Classified as a tetrapeptide oligopeptide directed at pancreatic tissue, Pancragen was developed to investigate how minimal peptide sequences interact with pancreatic cell models and glucose-regulation research systems. Its compact structure positions Pancragen as a useful research compound for studying tissue-specific peptide signaling in laboratory contexts.

At the cellular and molecular level, Pancragen is studied for its proposed ability to engage with chromatin and modulate transcriptional activity within pancreatic cell models, including acinar and islet cell research systems. Research observations within the Khavinson framework suggest that short bioregulator peptides may interact with specific DNA regions to influence the expression of genes associated with pancreatic enzyme synthesis, beta-cell signaling, and tissue homeostasis. These interactions are consistent with the broader proposition that short peptides act as gene-expression regulators within tissues from which their parent peptide complexes were originally extracted.

Research interest in Pancragen centers on pancreatic gene expression studies, beta-cell-related research, and investigations of glucose-regulation research models. Comparative work on tissue-specific bioregulators positions Pancragen alongside other pancreas-targeted oligopeptides used to explore peptidergic regulation of pancreatic biology in cell-culture and animal research models (Khavinson V.K., Anisimov V.N., 2009, Advances in Gerontology). Additional reports within the Khavinson tradition describe how short peptides modulate proliferation, differentiation, and apoptosis within target tissues, supporting continued laboratory investigation of Pancragen in pancreatic-biology research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

The development of short peptide bioregulators began in the 1970s at the Military Medical Academy in Saint Petersburg, where Professor Vladimir Khavinson and colleagues isolated peptide fractions from animal tissues that appeared to restore organ-specific function in experimental models. This work led to the founding of the Saint Petersburg Institute of Bioregulation and Gerontology and the systematic study of tissue-derived peptide complexes, including the pancreatic complex from which Pancragen was later derived.

Pancragen was identified within this research program as a synthetic tetrapeptide bioregulator associated with pancreatic tissue. Subsequent biochemical and molecular investigations explored how such peptides interact with chromatin structure and regulate transcriptional activity, supporting the hypothesis that minimal peptide sequences can act as tissue-specific gene-expression modulators within pancreatic cell systems.

Today, Pancragen is positioned within the wider family of Khavinson-school oligopeptides studied for pancreatic-tissue gene expression, beta-cell-related research, and peptidergic regulation of glucose-regulation research models in laboratory contexts.

1. Chromatin Interaction and Gene Expression

Within the Khavinson framework, Pancragen is proposed to interact with specific regions of double-stranded DNA and associated chromatin proteins, where it may influence the transcriptional activity of genes linked to pancreatic-tissue function. This proposed mode of action positions Pancragen as a tool for investigating peptide-mediated gene-expression regulation in pancreatic cell models.

2. Beta-Cell and Islet Signaling Pathways

Research observations suggest that Pancragen engages with signaling pathways relevant to islet cell function, including pathways associated with beta-cell signaling, insulin gene expression research, and glucose-regulation research models. These observations make Pancragen a useful compound for exploring tissue-specific peptide signaling in pancreatic cell-culture systems.

3. Acinar Cell and Exocrine Pancreas Research

Comparative work on short peptide bioregulators indicates effects on cellular proliferation, differentiation, and apoptosis within target tissues. In pancreatic-tissue research models, Pancragen is investigated for its role in acinar cell turnover studies, exocrine enzyme expression research, and pancreatic-tissue renewal pathways.

4. Adaptive and Homeostatic Signaling

Khavinson-school bioregulators are described as adaptive peptide regulators that operate under physiological stress conditions. Pancragen is studied for its proposed contribution to pancreatic-tissue homeostasis research, including models of age-related decline in pancreatic cell signaling and oxidative stress adaptation.

Research Applications

Conclusion

Pancragen is a Khavinson-school short peptide bioregulator studied for its proposed role in pancreatic-tissue gene expression and glucose-regulation research. Its compact tetrapeptide structure and tissue-targeted positioning make Pancragen a valuable laboratory compound for exploring peptidergic regulation of pancreatic biology in research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.